CYFRA 21-1 in non-small cell lung cancer - Standardisation and application during diagnosis

Collegium Antropologicum

Volumn 32, Issue 2, 2008, Pages 485-498

  Pavićević, Radomir ^a   Bubanović, Gordana ^a   Franjević, Ana ^a   Stančić Rokotov, Dinko ^a   Samaržija, Miroslav ^a  

^a University Hospital for Lung Diseases Jordanovac   (Croatia)

Author keywords

Contribution to diagnosis; CYFRA 21 1; Non small cell lung cancer; Standardisation; Tumour marker

Indexed keywords

ANTIGEN CYFRA21.1; KERATIN; TUMOR ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

AGED; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 52649178477     PISSN: 03506134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. LANDIS SH, MURRAY T, BOLDEN S, WINGO PA, Cancer J Clin, 49 (1999) 8.
2. TRAVIS WD, BRAMBILLA E, MÜLLER-HERMELINK HK, HARRIS CC, World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (IARC Press, Lyon, 2004).
3. Cancer Registry, Croatian Public Health Institute, accessed 14.5.2008. Available from: http//www.hzjz.hr/rak/novo.htm.
4. FERLAY J, BRAY F, PISANI P, PARKIN DM, Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No.5, version 2.0. (IARC Press, Lyonn, 2004).
5. GAZDAR AF, MINNA JD, J Natl Cancer Inst, 91 (1999) 299.
6. FONG KM, SEKIDO Y, GAZDAR AF, MINNA JD, Thorax, 58 (2003) 892.
7. HANAHAN D, WEINBERG RA, Cell, 100 (2000) 57.
8. SATO M, SHAMES DS, GAZDAR AF, MINNA JD, J Thorac Ocol, 2 (2007) 327.
9. PAVICEVIC R, Genetical factors in etiology of bronchopulmonary carcinoma - an analysis of quantitative and qualitative dermatoglyphic traits of the digito-palmar complex. PhD Thesis. In Croat (University of Zagreb, Zagreb, 1993).
10. MILICIC J, PAVICEVIC R, HALBAUER M, SARCEVIC B, Analysis of quantitative dermatoglyphic traits of the digito-palmar complex in carcinomas. In: DURHAM NM, FOX KH, PLATO CC (Eds) The state of dermatoglyphics - the science of finger and palm prints (Mellen Press, Lewiston, 2000).
11. RUDAN I, RUDAN P, Coll Antrop, 28 (2004) 483.
12. PUJOL JL, GRENIER J, DAURES JP, DAVER A, PUJOL H, MICHEL FB, Cancer Res, 53 (1993) 61.
13. STIEBER P, HASHOLZNER U, BODENMÜLLER H, NAGEL D, SUNDER-PLASSMANN L, DIENEMANN H, MEIER W, FATEH-MOGHADAM A, Cancer, 72 (1993) 707.
14. TAKADA M, MASUDA N, MATSUURA E, KUSUNOKI Y, MATUI K, NAKAGAWA K, YANA T, TUYUGUCHI I, OOHATA I, FUKUOKA M, Br J Cancer, 71 (1995) 160.
15. EBERT W, MULEY T, DRINGS P, Anticancer Res, 16 (1996) 2161.
16. LAI RS, HSU HK, LU JY, GER LP, LAI NS, Chest, 109 (1996) 995.
17. EBERT W, HOPPE M, MULEY T, DRINGS P, Anticancer Res, 17 (1997) 2875.
18. NISMAN B, LAFAIR J, HECHING N, LYASS O, BARAS M, PERETZ T, BARAK V, Cancer, 82 (1998) 1850.
19. SATOH H, ISHIKAWA S, KAMMA H, OHTSUKA M, HASEGAWA S, Eur J Cancer, 34 (1998) 1469.
20. SASSE EA, DOUMAS BT, MILLER WG, D'ORAZIO P, ECKFELDT JH, EVANS SA, GRAHAM GA, MYERS GL, PARSONS PJ, STANTON NV, How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline - Second Edition (NCCLS document C28-A2, Pennsylvania, 2000).
21. CHU PG, WEISS LM, Histopathology, 40 (2002) 403.
22. COULOMBE PA, OMARY MB, Curr Opin Cell Biol, 14 (2002) 110.
23. KU NO, OMARY MB, J Biol Chem, 270 (1995) 11820.
24. KU NO, OMARY MB, J Cell Biol, 127 (1994) 161.
25. KU NO, OMARY MB, J Biol Chem, 276 (2001) 26792.
26. KIRFEL J, MAGIN TM, REICHELT J, Cell Mol Life Sci, 60 (2003) 56.
27. BARAK V, GOIKE H, PANARETAKIS KW, EINARSSON R, Clin Biochem, 37 (2004) 529.
28. TRAVIS WD, COLBY TV, CORRIN B, SHIMOSATO Y, BRAMBILLA E, Histological typing of lung and pleural tumours (World Health Organisation, Geneva, 1999).
29. SOBIN LH, FLEMING ID, Cancer, 80 (1997) 1803.
30. INTERNATONAL UNION AGAINST CANCER (UICC), TNM Classification of Malignant Tumours (Wiley and Sons, New York, 2002).
31. GREENE FL, PAGE DL, FLEMING ID, FRITZ AG, BALCH CM, HALLER DG, MORROW M, AJCC Cancer Staging Manual (Springer, New York, 2002).
32. PAVIĆEVIĆ R, MILIČIĆ J, BUBANOVIĆ G, ŠUPE S, Coll Antropol, 22 (1998) 629.
33. PAVIĆEVIĆ R, BIALK P, MILIČIĆ J, BUBANOVIĆ G, PAVIĆEVIĆ L, Clinical applicability of tumour marker CYFRA 21-1 in NSCLC patients during a 20 - month period. In: Annals of Oncology ( 25 th European Society for Medical Oncology Congress, Hamburg, 2000).
34. PAVIĆEVIĆ R, BIALK P, BUBANOVIĆ G, KRAJNA A, SAMARŽIJA M, PAVIĆEVIĆ L, The prognostic value of tumour marker CYFRA 21-1 in NSCLC: A three year longitudinal study on 500 patients. In: Am J Respir Crit Care Med (97 th International Conference American Thoracic Society, San Francisco, 2001).
35. PAVIĆEVIĆ R, BUBANOVIĆ G, KRAJNA A, MILIČIĆ J, PAVELIĆ LJ, STANČIĆ-ROKOTOV D, BOBIĆ J, The evaluation of the tumour marker CYFRA 21-1 in the differentiation of malignat and benign pulmonary lesions. In: Am J Respir Crit Care Med (97th International Conference American Thoracic Society, San Francisco, 2001).
36. PAVIĆEVIĆ R, BUBANOVIĆ G, KRAJNA A, MILIČIĆ J, BIALK P, PAVIĆEVIĆ L, STANČIĆ-ROKOTOV D, Clinical contribution of tumour marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients. In: Eur Resp J (Annual Congress European Respiratory Society, Berlin, 2001).
37. KRAJNA A, PAVIĆEVIĆ R, BUBANOVIĆ G, ALERIĆ I, PAVLOVIĆ L, POPOVIĆ-GRLE S, Biodynamic approach to pretreatment level of tumour marker CYFRA 21-1 in differential diagnosis of single pulmonary nodules. In: Eur Resp J (13th Annual Congress European Respiratory Society, Vienna, 2003).
38. PAVIĆEVIĆ R, BUBANOVIĆ G, KRAJNA A, Improvement of Standard Treatment and Survival in 1870 NSCLC Patients by Follow-Up of CYFRA 21-1 Level for 60 Months. In: Proc Am Thorac Soc (International Conference American Thoracic Society, San Diego, 2005).
39. KRAJNA A, Determination of the level of tumour marker CYFRA 21-1 in single pulmonary nodules of different etiology. MS Thesis. In Croat (University of Zagreb, Zagreb, 2003).
40. BUBANOVIC G, Early recognition of local relapse of lung cancer by follow-up of tumour marker CYFRA 21-1 level. MS Thesis. In Croat (University of Zagreb, Zagreb, 2003).
41. BUBANOVIĆ G, PAVIĆEVIĆ R, KRAJNA A, Tumour marker ProGRP in diagnosis of small cell lung carcinoma. In: Proc Am Thorac Soc (International Conference American Thoracic Society, San Diego, 2005).
42. FRANJEVIĆ A, PAVIĆEVIĆ R, BUBANOVIĆ G, ICTP as an indicator of osteolytic bone metastasis. In: Am J Resp Crit Care Med (International Conference American Thoracic Society, San Francisco, 2007).
43. BUBANOVIĆ G, PAVIĆEVIĆ R, FRANJEVIĆ A, Biomarker SMRP in mesothelioma. In: Am J Resp crit Care Med (International Conference American Thoracic Society, San Francisco, 2007).
44. EBERT W, DIENEMANN H, FATEH-MOGHADAM A, SCHEULEN M, KONIETZKO N, SCHLEICH T, BOMBARDIERIE, Eur J Clin Chem Biochem, 32 (1994) 189.
45. SCHALHORN A, FUERST H, STIEBER P, J Lab Med, 25 (2001) 353.
46. MOLLINA R, FILELLA X, AUGE JM, FUENTES R, BOVER I, RIFA J, MORENO V, CANALS E, VINOLAS N, MARQUEZ A, BARREIRO E, BORRAS J, VILADIU P, Tumour Biol, 24 (2003) 209.
47. KULPA J, WOJCIK E, REINFUSS M, KOLODZIEJSKI L, Clin Chem, 48 (2002) 1931.
48. BARLESI F, GIMENEZ C, TORRE JP, DODDOLI C, MANCINI J, GREILLIER L, ROUX F, KLEISBAUER JP, Resp Med, 98 (2004) 357.
49. HUANG MS, JONG SB, TSAI MS, LIN MS, CHONG IW, LIN HC, HWANG JJ, Respir Med, 91 (1997) 135.
50. BUCCHERI G, TORCHIO P, FERRIGNO D, Chest, 124 (2003) 622.
51. PLEBANI M, BASSO D, NAVAGLIA F, DE PAOLI M, TOMMASINI A, CIPRIANI A, British Journal of Cancer, 72 (1995) 170.
52. MAEDA Y, SEGAWA Y, TAKIGAWA N, TAKATA I, FUJIMOTO N, Internal Medicine, 35 (1996) 764.
53. SATOH H, ISHIKAWA H, OHTSUKA M, SEKIZAWA K, Lung Cancer, 48 (2005) 151.
54. WIESKOPF B, DEMANGEAT C, PUROHIT A, STENGER R, PASCAL G, KREISMAN H, QUOIX E, Chest, 108 (1995) 163.
55. TREVISIANI L, PUTINATI S, SARTORI S, ABBASCIANO V, BAGNI B, Chest, 109 (1996) 104.
56. KIM YC, LIM SC, BOM HS, PARK KO, NA KJ, PARK HK, HWANG JH, Lung Cancer, 30 (2000) 187.
57. MOLLINA R, AGUSTI C, FILELLA X, JO J, JOSEPH J, GIMENEZ N, BALLESTA AM, Tumour Biol, 15 (1994) 318.
58. NAKAYAMA M, SATOH H, ISHIKAWA H, FUJIWARA M, KAMMA H, OHTSUKA M, SEKIZAWA K, Chest, 123 (2003) 2001.
59. STIEBER P, DIENEMANN H, HASHOLZNER U, FABRISIUS PG, SCHAMBECK C, WEINZIERL M, POLEY S, SAMTLEBEN W, HOFMANN K, MEIER W, Int J Biol Markers, 9 (1994) 82.
60. KULPA J, WOJCIK E, RADKOWSKI A, KOLODZIEJSKI L, STASIK Z, Anticancer Res, 20 (2000) 5035.
61. SCHNEIDER J, BITTERLICH N, VELCOVSKY HG, MORR H, KATZ N, EIGENBRODT E, Int J Clin Oncol, 7 (2002) 145.
62. BITTERLICH N, SCHNEIDER J, Anticancer Res, 27 (2007) 1933.
63. MIZUGUCHI S, NISHIYAMA N, IWATA T, NISHIDA T, IZUMI N, TSUKIOKA T, INOUE K, KAMEYAMA M, SUEHIRO S, Ann Thorac Surg, 83 (2007) 216.
64. MOLINA R, AUGE JM, FILELLA X, VINOLAS N, ALICARTE J, DOMINGO JM, BALLESTA AM, Anicancer Res, 25 (2005) 1773.